Plans to restrict open market access to tuberculosis medicines

India is tightening access to anti-TB drugs Bedaquiline and Delamanid due to rising drug-resistant tuberculosis cases and potential misuse after their patents expired. The Drugs Consultative Committee suggests licenses mandate use per national standards and conditional access via the National TB Elimination Programme. Packaging will include a warning label indicating use within the NTEP to ensure responsible usage.